Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in treatment-resistant migraine (CONQUER)
NCT03559257Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days at Month 3. Started Jul 2018; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03559257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559257.